PortfoliosLab logoPortfoliosLab logo
CHRS vs. CP
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CHRS vs. CP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Coherus BioSciences, Inc. (CHRS) and Canadian Pacific Kansas City Limited (CP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CHRS achieves a -0.70% return, which is significantly lower than CP's 21.24% return. Over the past 10 years, CHRS has underperformed CP with an annualized return of -25.65%, while CP has yielded a comparatively higher 12.76% annualized return.


CHRS

1D
-4.08%
1M
-2.76%
6M
-34.72%
YTD
-0.70%
1Y
60.63%
3Y*
-32.03%
5Y*
-35.92%
10Y*
-25.65%
ALL TIME*
-17.11%

CP

1D
0.83%
1M
1.25%
6M
20.08%
YTD
21.24%
1Y
23.04%
3Y*
3.86%
5Y*
4.52%
10Y*
12.76%
ALL TIME*
10.35%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$622.50K$1.07M$1.63M
$233.07M$226.64M$247.01M

CHRS vs. CP - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CHRS
Coherus BioSciences, Inc.
-0.70%2.90%-58.56%-57.95%-50.38%-8.17%-3.47%98.95%2.84%-68.74%
CP
Canadian Pacific Kansas City Limited
21.24%2.60%-7.84%6.85%4.71%4.64%37.33%45.04%-1.81%29.32%

Correlation

The correlation between CHRS and CP is 0.13, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.13

Correlation (3Y)
Balances recent behavior with more history.

0.19

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.20

Correlation (10Y)
Provides a long-term view across more market conditions.

0.20

Correlation (All Time)
Calculated using the full available price history since Nov 6, 2014

0.20

Fundamentals

Market Cap

CHRS:

$172.60M

CP:

$78.14B

EPS

CHRS:

$1.50

CP:

$4.85

PE Ratio

CHRS:

0.94

CP:

18.31

PS Ratio

CHRS:

3.74

CP:

4.91

Total Revenue (TTM)

CHRS:

$46.88M

CP:

$16.44B

Gross Profit (TTM)

CHRS:

$23.41M

CP:

$7.68B

EBITDA (TTM)

CHRS:

-$162.15M

CP:

$9.05B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CHRS vs. CP — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

CHRS
CHRS Risk / Return Rank: 6666
Overall Rank
CHRS Sharpe Ratio Rank: 6666
Sharpe Ratio Rank
CHRS Sortino Ratio Rank: 6868
Sortino Ratio Rank
CHRS Omega Ratio Rank: 6565
Omega Ratio Rank
CHRS Calmar Ratio Rank: 6868
Calmar Ratio Rank
CHRS Martin Ratio Rank: 6363
Martin Ratio Rank

CP
CP Risk / Return Rank: 7373
Overall Rank
CP Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
CP Sortino Ratio Rank: 7171
Sortino Ratio Rank
CP Omega Ratio Rank: 6868
Omega Ratio Rank
CP Calmar Ratio Rank: 7676
Calmar Ratio Rank
CP Martin Ratio Rank: 7676
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

CHRS vs. CP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Coherus BioSciences, Inc. (CHRS) and Canadian Pacific Kansas City Limited (CP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CHRSCPDifference
Sharpe ratioReturn per unit of total volatility

-0.34

Sortino ratioReturn per unit of downside risk

-0.12

Omega ratioGain probability vs. loss probability

1.17

1.18

-0.01

Calmar ratioReturn relative to maximum drawdown

1.10

1.68

-0.58

Martin ratioReturn relative to average drawdown

1.82

3.99

-2.17

CHRS vs. CP - Sharpe Ratio Comparison

The current CHRS Sharpe Ratio is 0.63, which is lower than the CP Sharpe Ratio of 0.97. The chart below compares the historical Sharpe Ratios of CHRS and CP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CHRS vs. CP - Drawdown Comparison

The maximum CHRS drawdown since its inception was -98.21%, which is greater than CP's maximum drawdown of -69.17%. Use the drawdown chart below to compare losses from any high point for CHRS and CP.


Loading charts...

Drawdown Indicators


CHRSCPDifference

Max Drawdown

Largest peak-to-trough decline

-98.21%

-69.17%

-29.04%

Max Drawdown (1Y)

Largest decline over 1 year

-45.82%

-13.10%

-32.72%

Max Drawdown (3Y)

Largest decline over 3 years

-87.71%

-25.88%

-61.83%

Max Drawdown (5Y)

Largest decline over 5 years

-96.47%

-25.88%

-70.59%

Max Drawdown (10Y)

Largest decline over 10 years

-97.88%

-33.70%

-64.18%

Current Drawdown

Current decline from peak

-96.24%

-5.14%

-91.10%

Average Drawdown

Average peak-to-trough decline

-63.91%

-20.24%

-43.67%

Ulcer Index

Depth and duration of drawdowns from previous peaks

27.56%

5.51%

+22.05%

Volatility

CHRS vs. CP - Volatility Comparison

Coherus BioSciences, Inc. (CHRS) has a higher volatility of 16.17% compared to Canadian Pacific Kansas City Limited (CP) at 6.30%. This indicates that CHRS's price experiences larger fluctuations and is considered to be riskier than CP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CHRSCPDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.17%

6.30%

+9.87%

Volatility (6M)

Calculated over the trailing 6-month period

48.53%

16.47%

+32.06%

Volatility (1Y)

Calculated over the trailing 1-year period

79.77%

22.84%

+56.93%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

84.99%

24.38%

+60.61%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

74.25%

25.49%

+48.76%

Dividends

CHRS vs. CP - Dividend Comparison

CHRS has not paid dividends to shareholders, while CP's dividend yield for the trailing twelve months is around 0.77%.


PositionTTM20252024202320222021202020192018201720162015
CHRS
Coherus BioSciences, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
CP
Canadian Pacific Kansas City Limited
0.77%0.86%0.76%0.78%0.96%0.84%0.76%0.93%1.07%0.92%0.98%0.98%

Financials

CHRS vs. CP - Financials Comparison

This section allows you to compare key financial metrics between Coherus BioSciences, Inc. and Canadian Pacific Kansas City Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


CHRS and CP have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CHRS has higher volatility (16.17%) compared to CP (6.30%). In terms of maximum drawdown, CHRS dropped -98.21% vs CP's -69.17%.

CP currently has the higher Sharpe Ratio (0.97 vs 0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CHRS and CP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer